Richard C. Malabre - 09 Jun 2025 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, Chief Accounting Officer
Signature
/s/Carolyn Rucci, attorney-in-fact for Richard C. Malabre
Issuer symbol
AKBA
Transactions as of
09 Jun 2025
Net transactions value
-$34,950
Form type
4
Filing time
11 Jun 2025, 17:13:30 UTC
Previous filing
05 Jun 2025
Next filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Malabre Richard C SVP, Chief Accounting Officer C/O AKEBIA THERAPEUTICS, INC, 245 FIRST ST., CAMBRIDGE /s/Carolyn Rucci, attorney-in-fact for Richard C. Malabre 11 Jun 2025 0002007730

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Options Exercise $25,200 +15,000 +5.6% $1.68 281,914 09 Jun 2025 Direct F1
transaction AKBA Common Stock Sale $60,150 -15,000 -5.3% $4.01 266,914 09 Jun 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Stock Option (Right to buy) Options Exercise $0 -15,000 -4.5% $0.000000 321,000 09 Jun 2025 Common Stock 15,000 $1.68 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This stock option exercise was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024.
F2 This sale was made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024.
F3 The shares were sold at prices ranging from $4.00 to $4.03 and the price reported reflects the weighted average sale price.
F4 The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.